Updated on 2025/05/12

Information

 

写真a

 
GOTO SHUNSUKE
 
Organization
Kyushu University Hospital Urology Assistant Professor
School of Medicine Department of Medicine(Concurrent)
Title
Assistant Professor
Profile
泌尿器科における臨床業務 泌尿器科癌に関する基礎および臨床研究 臨床泌尿器科領域に関する講義、実習等での指導
External link

Degree

  • MD, PhD

Papers

  • Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models Reviewed International journal

    Shunsuke Goto, Yukimi Sakoda, Keishi Adachi, Yoshitaka Sekido, Seiji Yano, Masatoshi Eto, Koji Tamada

    CANCER IMMUNOLOGY IMMUNOTHERAPY   70 ( 9 )   2503 - 2515   2021.9

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Chimeric antigen receptor (CAR)-T cell therapy has impressive efficacy in hematological malignancies, but its application in solid tumors remains a challenge. Multiple hurdles associated with the biological and immunological features of solid tumors currently limit the application of CAR-T cells in the treatment of solid tumors. Using syngeneic mouse models, we recently reported that CAR-T cells engineered to concomitantly produce interleukin (IL)-7 and chemokine (C-C motif) ligand 19 (CCL19)-induced potent anti-tumor efficacy against solid tumors through an improved ability of migration and proliferation even in an immunosuppressive tumor microenvironment. In this study, for a preclinical evaluation preceding clinical application, we further explored the potential of IL-7/CCL19-producing human CAR-T cells using models that mimic the clinical features of solid tumors. Human anti-mesothelin CAR-T cells producing human IL-7/CCL19 achieved complete eradication of orthotopic pre-established malignant mesothelioma and prevented a relapse of tumors with downregulated antigen expression. Moreover, mice with patient-derived xenograft of mesothelin-positive pancreatic cancers exhibited significant inhibition of tumor growth and prolonged survival following treatment with IL-7/CCL19-producing CAR-T cells, compared to treatment with conventional CAR-T cells. Transfer of IL-7/CCL19-producing CAR-T cells resulted in an increase in not only CAR-T cells but also non-CAR-T cells within the tumor tissues and downregulated the expression of exhaustion markers, including PD-1 and TIGIT, on the T cells. Taken together, our current study elucidated the exceptional anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells and their potential for clinical application in the treatment of patients with solid tumors.

    DOI: 10.1007/s00262-021-02853-3

  • Novel immune drug combination induces tumour microenvironment remodelling and reduces the dosage of anti-PD-1 antibody

    Ozasa, T; Nakajima, M; Tsunedomi, R; Goto, S; Adachi, K; Takahashi, H; Tamada, K; Nagano, H

    SCIENTIFIC REPORTS   15 ( 1 )   8956   2025.3   ISSN:2045-2322

     More details

    Language:English   Publisher:Scientific Reports  

    Immune checkpoint inhibitors (ICIs) are effective in clinical settings; however, they present immune-related adverse effects and financial burden. Although dose reduction of ICIs may mitigate these limitations, it could compromise therapeutic efficacy. Using two adjuvants (poly(I:C) and LAG-3-Ig) combined with three neoantigen peptides (Comb), we examined whether Comb could enhance the efficacy of reduced dose of αPD-1 monoclonal antibody (RD-αPD-1 mAb), which has limited efficacy. In a murine colorectal cancer model using an MC38 cell line, Comb addition to RD-αPD-1 mAb enhanced treatment efficacy. Analysis of the tumour microenvironment (TME) in mice treated with Comb using flow cytometry and single-cell RNA sequencing revealed decreased macrophages with highly expressing immunosuppressive genes and increased plasmacytoid dendritic cells with highly expressing antigen-presenting genes. A potent infiltration of CD8+ tumour-infiltrating lymphocytes (TILs) with an effector profile was only observed in RD-αPD-1 mAb with Comb. Additionally, single-cell T cell receptor repertoire analysis underscored an oligoclonal expansion of CD8+ TILs following treatment with RD-αPD-1 mAb with Comb. This novel immune drug combination may be a promising strategy for reducing αPD-1 mAb dosage while preserving antitumour efficacy through modulating the TME.

    DOI: 10.1038/s41598-025-87344-6

    Web of Science

    Scopus

    PubMed

  • Analysis of Tumor Immune Microenvironment in the Upper Tract Urothelial Carcinoma with Intravesical Recurrence

    Ito, D; Tanegashima, T; Okumura, G; Itahashi, K; Tsukahara, S; Mutaguchi, J; Goto, S; Kobayashi, S; Matsumoto, T; Shiota, M; Koyama, S; Nishikawa, H; Eto, M

    CANCER SCIENCE   116   55 - 55   2025.1   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Laparoscopic Retroperitoneal Lymph Node Dissection After Chemotherapy for Nonseminomatous Testicular Germ-Cell Tumor at a Single Center

    Shiota, M; Tanegashima, T; Tsukahara, S; Mutaguchi, J; Goto, S; Kobayashi, S; Matsumoto, T; Eto, M

    ASIAN JOURNAL OF ENDOSCOPIC SURGERY   18 ( 1 )   e13416   2025.1   ISSN:1758-5902 eISSN:1758-5910

     More details

    Language:English   Publisher:Asian Journal of Endoscopic Surgery  

    Objective: This study investigated the perioperative and oncological outcomes of laparoscopic retroperitoneal lymph node dissection (RPLND) procedures for post-chemotherapy patients with nonseminomatous testicular germ-cell tumor at a single center. Methods: This study included patients with nonseminomatous testicular cancer who underwent RPLND after chemotherapy at the Kyushu University Hospital between 2016 and 2024. The preoperative clinicopathological characteristics, perioperative outcomes, and oncological outcomes were investigated. Results: A total of 13 patients underwent laparoscopic RPLND. Median maximum retroperitoneal tumor size at post-chemotherapy before RPLND was 11 mm (range, 2–30 mm). RPLND template was one side and both sides in nine and four patients. Median operative time was 272 min (range, 129–490 min), and median estimated blood loss was 27 mL (range, 0–100 mL). Median time from operation to discharge was 8 days (range, 5–15 days). There was no severe perioperative and postoperative complication. Residual cancer and teratoma were detected in one and seven patients. During median follow-up of 18.6 months (range, 1.0–95.7 months), no case presented recurrence. Conclusion: Laparoscopic RPLND presented safety in perioperative outcomes and favorable oncological outcomes. Thus, it was confirmed that laparoscopic RPLND is a feasible minimally invasive procedure for selected cases.

    DOI: 10.1111/ases.13416

    Web of Science

    Scopus

    PubMed

  • Independent validation of genetic risk model to progression after intravesical BCG therapy for NMIBC

    Nagakawa, S; Shiota, M; Tsukahara, S; Tanegashima, T; Ueda, S; Mutaguchi, J; Goto, S; Kobayashi, S; Matsumoto, T; Eto, M

    CANCER SCIENCE   116   1513 - 1513   2025.1   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Laparoscopic Retroperitoneal Lymph Node Dissection After Chemotherapy for Nonseminomatous Testicular Germ-Cell Tumor at a Single Center(タイトル和訳中)

    Shiota Masaki, Tanegashima Tokiyoshi, Tsukahara Shigehiro, Mutaguchi Jun, Goto Shunsuke, Kobayashi Satoshi, Matsumoto Takashi, Eto Masatoshi

    Asian Journal of Endoscopic Surgery   18 ( 1 )   ases.13416 - ases.13416   2025   ISSN:1758-5902

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

  • Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration-resistant prostate cancer patients

    Tanegashima, T; Shiota, M; Tsukahara, S; Mutaguch, J; Goto, S; Kobayashi, S; Matsumoto, T; Eto, M

    PROSTATE   84 ( 14 )   1329 - 1335   2024.10   ISSN:0270-4137 eISSN:1097-0045

     More details

    Language:English   Publisher:The Prostate  

    BACKGROUND: Proton pump inhibitors (PPIs) are widely used due to their affordability and minimal severe side effects. However, their influence on the efficacy of cancer treatments, particularly androgen receptor signaling inhibitors (ARSIs), remains unclear. This study investigates the impact of PPI usage on the treatment outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS: A total of 117 mCRPC patients were retrospectively analyzed and divided into two groups based on the concomitant use of PPI at the initiation of ARSI treatment: PPI+ (n = 38) and PPI- (n = 79). Patient characteristics, including age at ARSI treatment administered, prostate-specific antigen (PSA) value at ARSI treatment administered, International Society of Urological Pathology grade group at prostate biopsy, metastatic site at ARSI treatment administered, prior docetaxel (DTX) treatment, and type of ARSI (abiraterone acetate or enzalutamide) were recorded. Progression-free survival (PFS), overall survival (OS), and PSA response rates were compared between the two groups. Patients were further stratified by clinical background to compare PFS and OS between the two groups. RESULTS: The PPI- group exhibited significantly extended PFS and a trend toward improved OS. For PSA response (reduction of 50% or more from baseline), the rates were 62.3% and 45.9% in the PPI- group and the PPI+ group, respectively. For deep PSA response (reductions of 90% or more from baseline), the rates were 36.4% and 24.3% in the PPI- group and the PPI+ group, respectively. The effects were consistent across subgroups divided by prior DTX treatment and type of ARSI administered. CONCLUSIONS: The administration of PPIs appears to diminish the therapeutic efficacy of ARSIs in mCRPC patients. Further prospective studies are needed to confirm these findings and explore the biological mechanisms involved.

    DOI: 10.1002/pros.24769

    Web of Science

    Scopus

    PubMed

  • Optimization of Extended Pelvic Lymph Node Dissection Side for Prostate Cancer

    Shiota, M; Shimbo, M; Tsukahara, S; Tanegashima, T; Mutaguchi, J; Goto, S; Kobayashi, S; Matsumoto, T; Hattori, K; Endo, F; Eto, M

    ANNALS OF SURGICAL ONCOLOGY   31 ( 13 )   8986 - 8992   2024.9   ISSN:1068-9265 eISSN:1534-4681

     More details

    Language:English   Publisher:Annals of surgical oncology  

    BACKGROUND: This study aimed to show the association between tumor location and laterality of positive lymph nodes by evaluating biopsy and magnetic resonance imaging (MRI) findings, and to optimize the extended pelvic lymph node dissection (ePLND) side for prostate cancer. METHODS: The study enrolled patients who underwent robot-assisted radical prostatectomy with ePLND. Tumor locations were determined according to International Society of Urological Pathology grade group 4/5 in biopsies and Prostate Imaging-Reporting and Data System category 4/5 in MRI results. The concordance of tumor location lobe and positive lymph node side with the performance of tumor location-guided ePLND for positive lymph node detection was evaluated. RESULTS: For 301 patients who underwent ePLND at Kyushu University Hospital, tumor locations determined by biopsy and MRI findings showed no lesion in 8 (2.7%) patients, unilateral lobe in 223 (74.1%) patients, and bilateral lobe in 70 (23.3%) patients. The accuracies for detection of any and all positive lymph nodes by tumor location-guided unilateral ePLND were 99.6% and 97.3%, respectively. Among the patients at St. Luke's International Hospital, the accuracies for detection of any and all positive lymph nodes by tumor location-guided unilateral ePLND were estimated to be 99.0% and 97.3%, respectively. CONCLUSIONS: This study proposed tumor location-guided ePLND according to biopsy and MRI findings. This novel strategy is expected to reduce the burden of bilateral ePLND at the cost of acceptable risk of failing to detect positive lymph nodes.

    DOI: 10.1245/s10434-024-16294-6

    Web of Science

    Scopus

    PubMed

  • Functional outcomes in robot-assisted partial nephrectomy with three-dimensional images reconstructed from computed tomography: a propensity score-matched comparative analysis

    Kobayashi, S; Tsukino, K; Mutaguchi, J; Tanegashi, T; Goto, S; Matsumoto, T; Shiota, M; Eto, M

    JOURNAL OF ROBOTIC SURGERY   18 ( 1 )   314   2024.8   ISSN:1863-2483 eISSN:1863-2491

     More details

    Language:English   Publisher:Journal of Robotic Surgery  

    Our objective was to investigate the long-term functional outcomes of robot-assisted partial nephrectomy (RAPN) combined with three-dimensional (3D) imaging. The 3D images, reconstructed using computed tomography, were introduced in RAPN procedures. The demographic, oncological, functional, and volumetric outcomes of 296 patients who underwent RAPN with and without 3D imaging between 2013 and 2021 were analyzed retrospectively. Propensity score matching (1:1) was performed to adjust for potential baseline confounders. After matching, 71 patients were allocated to each group. In the 3D RAPN (3DRPN) group, functional outcomes significantly improved: the number of patients with over 90% estimated glomerular filtration rate (eGFR) preservation rate (40 vs. 43, P = 0.044), eGFR preservation rate (88.0% vs. 91.6%, P = 0.006), the number of patients with chronic kidney disease (CKD) upstaging (26 vs. 13, P = 0.023), and split renal function preservation rate (operated kidney: 84.9% vs. 88.5%, P = 0.015). The 3DRPN group showed superiority in terms of >90% eGFR preservation (P = 0.010), CKD upstaging-free survival rates (P < 0.001), and volumetric outcomes (excess parenchymal volume: 27.9 vs. 17.7 mL, P = 0.030; parenchyma volume preservation rate: 81.6% vs. 88.8%, P = 0.006). Three-dimensional imaging was positively associated with eGFR preservation (P = 0.023, odds ratio: 2.34) and prevention of CKD upstaging (P = 0.013, odds ratio: 2.90). In this study, RAPN combined with 3D imaging underscored the preservation of eGFR > 90% and the prevention of CKD upstaging by improving the preservation rate of renal parenchyma and split renal function.

    DOI: 10.1007/s11701-024-02070-x

    Web of Science

    Scopus

    PubMed

  • Current status and future perspective of immunotherapy for renal cell carcinoma

    Blas, L; Monji, K; Mutaguchi, J; Kobayashi, S; Goto, S; Matsumoto, T; Shiota, M; Inokuchi, J; Eto, M

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   29 ( 8 )   1105 - 1114   2024.8   ISSN:1341-9625 eISSN:1437-7772

     More details

    Language:English   Publisher:International Journal of Clinical Oncology  

    In the last decade, the standard treatment for advanced renal cell carcinoma (RCC) has evolved, mainly driven by the development and approval of immune checkpoint inhibitors (ICIs). Currently, ICI monotherapy and ICI-based combinations with tyrosine kinase inhibitors and targeted therapies against mammalian target of rapamycin or vascular endothelial growth factor have become new standard treatments for first-line and subsequent-line therapies. ICIs play an important role as an adjuvant postoperative therapy, and this field is the subject of active research. Furthermore, ongoing randomized controlled trials are investigating the clinical value of more intense treatments by combining multiple effective treatments for RCC. Additionally, novel biomarkers for prognosis have been investigated. This study reviews the current evidence on immunotherapy as a treatment for RCC patients, randomized controlled trials, and ongoing studies including RCC patients and recent findings, and discusses future perspectives.

    DOI: 10.1007/s10147-023-02446-3

    Web of Science

    Scopus

    PubMed

  • Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy

    Blas, L; Shiota, M; Tanegashima, T; Tsukahara, S; Ueda, S; Mutaguchi, J; Goto, S; Kobayashi, S; Matsumoto, T; Inokuchi, J; Eto, M

    INTERNATIONAL JOURNAL OF UROLOGY   31 ( 4 )   404 - 408   2024.4   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publisher:International Journal of Urology  

    Background: Early detection of biochemical recurrence (BCR) after radical prostatectomy (RP) is crucial for early treatment and improving survival outcomes. The optimal prostate-specific antigen (PSA) monitoring remains unclear, and several models have been proposed. We aimed to externally validate four models for optimal PSA monitoring after RP and propose modifications to improve them. Methods: We reviewed the clinicopathological data of 896 patients who underwent robot-assisted RP between 2009 and 2022. We examined all PSA values and estimated the PSA value for four monitoring schedules at each time point in the virtual follow-up. We defined the ideal PSA for BCR detection between 0.2 and 0.4 ng/mL. Results: During the median follow-up of 21.4 months, 128 (14.3%) patients presented BCR. The original and modified Keio models, National Cancer Center Hospital model, and American Urological Association/American Society for Radiation Oncology model detected BCR in 14 (10.9%), three (2.3%), 12 (9.4%), and 11 (8.6%) patients with PSA >0.4 ng/mL. Most patients experienced BCR detected with PSA >0.4 ng/mL during the first year postoperative. The modification of interval within 6 months postoperative avoided BCR detection with PSA >0.4 ng/mL within the first year postoperative in 8/9 (88.9%), 1/2 (50.0%), 5/6 (83.3%), and 4/4 (100%) for the original and modified Keio models, National Cancer Center Hospital model, and American Urological Association/American Society for Radiation Oncology model, respectively. Conclusion: We validated four models for PSA monitoring after RP to detect BCR and suggested modifications to avoid detections out of the desired range of PSA. These modifications could help to establish an optimal PSA monitoring schedule after RP.

    DOI: 10.1111/iju.15379

    Web of Science

    Scopus

    PubMed

  • 根治的前立腺摘除術後の最適な前立腺特異抗原モニタリングスケジュールの検証(Validation of schedules for optimal prostate-specific antigen monitoring after radical prostatectomy)

    Blas Leandro, Shiota Masaki, Tanegashima Tokiyoshi, Tsukahara Shigehiro, Ueda Shohei, Mutaguchi Jun, Goto Shunsuke, Kobayashi Satoshi, Matsumoto Takashi, Inokuchi Junichi, Eto Masatoshi

    International Journal of Urology   31 ( 4 )   404 - 408   2024.4   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    根治的前立腺摘除術(RP)後に行う前立腺特異抗原(PSA)モニタリングの4つのモデルの妥当性を検証し、生化学的再発(BCR)検出を改善する修正モデルを検討した。2009~2022年にロボット支援RPを受けた患者の臨床病理学的データを調べ、4つのモデルで仮想上経過観察時のPSA値を推定した。BCR検出に最適なPSA値は0.2~0.4ng/mLと定義した。患者896例(年齢中央値66歳)を解析した。追跡期間中央値21.4ヵ月の間に128例(14.3%)がBCRを認めた。BCRが検出されたPSA値0.4ng/mL超の患者は、慶應モデル、修正慶應モデル、国立がん研究センター中央病院(NCCH)モデル、および米国泌尿器科学会(AUA)/米国放射線腫瘍学会(ASTRO)モデルでそれぞれ14例(10.9%)、3例(2.3%)、12例(9.4%)、および11例(8.6%)であった。殆どの患者は、術後1年目にPSA値0.4ng/mL超でBCRが検出された。術後6ヵ月以内の間隔に変更すると、術後1年以内のPSA>0.4ng/mLのBCR検出は上記のモデルそれぞれで8/9例(88.9%)、1/2例(50.0%)、5/6(83.3%)、4/4例(100%)で回避された。以上より、RP後のBCR検出のためのPSAモニタリングを最適にするための修正案が示唆された。

  • An innovate segmentation system by implementing dilated convolution and red channel enhanced images in cystoscopic images

    Mutaguchi, J; Morooka, K; Goto, S; Kobayashi, S; Matsumoto, T; Shiota, M; Inokuchi, J; Eto, M

    EUROPEAN UROLOGY   85   S377 - S377   2024.3   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy to the prostate. Reviewed International journal

    @Shiota M, @Tsukahara S, @Takamatsu D, @Tanegashima T, @Ueda S, #Blas L, @Goto S, @Kobayashi S, @Matsumoto T, @Inokuchi J, @Shioyama Y, @Eto M.

    Asian J Endosc Surg   2024.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy to the prostate

    Shiota, M; Tsukahara, S; Takamatsu, D; Tanegashima, T; Ueda, S; Blas, L; Goto, S; Kobayashi, S; Matsumoto, T; Inokuchi, J; Shioyama, Y; Eto, M

    ASIAN JOURNAL OF ENDOSCOPIC SURGERY   17 ( 1 )   e13279   2024.1   ISSN:1758-5902 eISSN:1758-5910

     More details

    Language:English   Publisher:Asian Journal of Endoscopic Surgery  

    Purpose: This study presents the surgical and oncological outcomes of salvage robot-assisted radical prostatectomy (RARP) after carbon ion radiotherapy at a single institution. Methods: Patients who underwent salvage RARP for local recurrence after carbon ion radiotherapy at Kyushu University Hospital between 2020 and 2023 were included. A single surgeon performed salvage RARP with extended pelvic lymph node dissection. Clinicopathological characteristics and perioperative and postoperative outcomes were prospectively collected and electronically recorded. Results: Ten cases were included. The preoperative clinical T-stage was T2, except for one case with T3a. The median console time was 171 min (range, 135–226 min). No severe perioperative or postoperative complications were noted. The pathological T-stage was T2, T3a, and T3b in four, four, and two cases, respectively. Biochemical recurrence was observed in one patient at 31.2 months after surgery. For patients with more than 1 year of follow-up, urinary continence recovery with ≤1 pad was achieved in two cases within 1 year, whereas four cases did not recover urinary continence within 1 year. Conclusions: This case series demonstrated the feasibility of salvage RARP after carbon ion radiotherapy. Although the urinary continence recovery was modest, short-term disease control was favorable.

    DOI: 10.1111/ases.13279

    Web of Science

    Scopus

    PubMed

  • 前立腺に対する炭素イオン線治療後のサルベージロボット支援前立腺全摘術(Salvage robot-assisted radical prostatectomy after carbon ion radiotherapy to the prostate)

    Shiota Masaki, Tsukahara Shigehiro, Takamatsu Dai, Tanegashima Tokiyoshi, Ueda Shohei, Blas Leandro, Goto Shunsuke, Kobayashi Satoshi, Matsumoto Takashi, Inokuchi Junichi, Shioyama Yoshiyuki, Eto Masatoshi

    Asian Journal of Endoscopic Surgery   17 ( 1 )   ases.13279 - ases.13279   2024.1   ISSN:1758-5902

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    前立腺癌に対する炭素イオン線治療(CIRT)後のサルベージロボット支援前立腺全摘術(RARP)の手術アウトカムと腫瘍アウトカムについて検討した。2020~2023年に、CIRT後に局所再発をきたしてRARPを施行された前立腺癌患者10例(中央値69歳)を対象とした。拡大骨盤リンパ節郭清(PLND)によるサルベージRARPを行い、臨床病理学的特徴、周術期アウトカムおよび術後アウトカムを評価した。CIRT後の局所再発時のPSA中央値は4.02ng/mL、生検によるGleason分類ではグレードIIが1例、グレードIIIが2例、グレードIVが2例、グレードVが5例であり、術前の臨床的Tステージは9例がT2、1例のみT3a、初期診断から局所再発までは中央値58.5ヵ月であった。RARPに際して全例にPLND、1例に両側神経温存手術を行い、手術時間中央値は235分、コンソール時間中央値は171分、推定出血量中央値は150mLであった。直腸損傷といった周術期合併症や術後90日以内の再入院、尿道狭窄は認められなかった。腫瘍アウトカムに関して、1例が術後31.2ヵ月に生化学的再発を呈した。CIRT後に局所再発をきたした前立腺癌患者に対して、RARPは実行可能な手技であることが示された。

  • Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation. Reviewed International journal

    @Shiota M, @Tsukahara S, @Ueda S, @Mutaguchi J, @Goto S, @Kobayashi S, @Matsumoto T, #Blas L, @Monji K, @Inokuchi J, @Eto M:

    J Robot Surg   2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation

    Shiota, M; Tsukahara, S; Ueda, S; Mutaguchi, J; Goto, S; Kobayashi, S; Matsumoto, T; Blas, L; Monji, K; Inokuchi, J; Eto, M

    JOURNAL OF ROBOTIC SURGERY   17 ( 6 )   2721 - 2728   2023.12   ISSN:1863-2483 eISSN:1863-2491

     More details

    Language:English   Publisher:Journal of Robotic Surgery  

    The novel technique of lateral pelvic fascia preservation (LPFP) in robot-assisted radical prostatectomy (RARP) has been reported to improve urinary continence recovery. We aimed to investigate surgical and oncological outcomes after RARP using the LPFP technique and compare them with conventional RARP. This study included patients who underwent RARP with and without the LPFP technique. Time to urinary continence recovery was compared between the LPFP and non-LPFP groups using univariate, multivariate, and propensity-score matched analysis. Perioperative and postoperative outcomes were compared between the two groups using univariate analysis. We included 139 patients who underwent RARP, 68 in the LPFP group and 71 in the non-LPFP group. The LPFP technique was associated with a shorter time to urinary continence recovery, a shorter operative time and lower estimated blood loss. Surgical and oncological outcomes, including complications, pathological T-stage, surgical margin status, and biochemical recurrence-free survival, were comparable between the two groups. This study demonstrated that the LPFP technique improves urinary continence recovery and operative times without compromising surgical and oncological outcomes. The use of this technique in patients with clinically localized prostate cancer is recommended.

    DOI: 10.1007/s11701-023-01702-y

    Web of Science

    Scopus

    PubMed

  • Current evidences in the first-line treatment of metastatic non-clear cell renal cell carcinoma

    Inokuchi, J; Goto, S; Monji, K; Eto, M

    ANNALS OF ONCOLOGY   34   S1362 - S1362   2023.11   ISSN:0923-7534 eISSN:1569-8041

  • Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies. Reviewed International journal

    @Kashiwagi E, @Shiota M, @Inokuchi J, @Tsukahara S, @Imada K, @Monji K, @Goto S, @Matsumoto T, @Eto M:

    Anticancer Res   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Comparison of Testosterone Level of Seminal Vesicle Fluid in Patients With Prostate Cancer Versus Other Malignancies

    Kashiwagi, E; Shiota, M; Inokuchi, J; Tsukahara, S; Imada, K; Monji, K; Goto, S; Matsumoto, T; Eto, M

    ANTICANCER RESEARCH   43 ( 9 )   4249 - 4254   2023.9   ISSN:0250-7005 eISSN:1791-7530

     More details

    Language:English   Publisher:Anticancer Research  

    Background/Aim: Testosterone is essential for prostate cancer development and growth. This study aimed to investigate the relationship between testosterone in seminal vesicles and prostate cancer incidence and its malignant phenotype. Patients and Methods: After obtaining institutional review board approval, seminal vesicle fluid samples were collected from patients who underwent prostatectomy or cystectomy. Pathological review demonstrated that 26 patients had benign prostate tissue and 149 had prostate cancer. First, testosterone levels in seminal vesicle fluid from benign prostate and prostate cancer samples were compared. Next, the relationship between pathological stage, International Society of Urological Pathology (ISUP) score, and testosterone concentrations in seminal vesicle fluid in the prostate cancer group were examined. Results: Testosterone in seminal vesicles was significantly higher in the prostate cancer group [median (range), 1.94 (0.17-4.32) ng/ml] than in the benign prostate group (mainly bladder cancer) [1.45 (0.60-2.78) ng/ml] (p=0.001). Testosterone in seminal vesicles showed no difference in relation to pathological stage (pT2 vs. pT3) or ISUP score (12 vs. 345) (p=0.480 and p=0.964, respectively). Neoadjuvant chemotherapy for other cancers (e.g., bladder or rectal cancer) significantly reduced testosterone in seminal vesicles (p=0.013). Multivariate regression analysis revealed that testosterone in seminal vesicles was significantly correlated with prostate cancer, and not with neoadjuvant chemotherapy (p=0.023, p=0.457, respectively). Conclusion: Testosterone in seminal vesicles may contribute to prostate cancer incidence, but has no relationship with pathological grading.

    DOI: 10.21873/anticanres.16618

    Web of Science

    Scopus

    PubMed

  • Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naïve men. Reviewed International journal

    #Blas L, @Shiota M, @Tsukahara S, @Goto S, @Kinoshita F, @Matsumoto T, @Monji K, @Kashiwagi E, @Inokuchi J, @Eto M:

    Int J Urol   2023.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naive men

    Blas, L; Shiota, M; Tsukahara, S; Goto, S; Kinoshita, F; Matsumoto, T; Monji, K; Kashiwagi, E; Inokuchi, J; Eto, M

    INTERNATIONAL JOURNAL OF UROLOGY   30 ( 7 )   600 - 604   2023.7   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publisher:International Journal of Urology  

    Objective: The precise diagnosis of prostate cancer (PC) is crucial to avoid underdiagnosis, overdiagnosis, and overtreatment. We aimed to compare clinically significant PC (csPC) detection between MRI/ultrasound fusion-targeted prostate (TBx) compared to systematic biopsy (SBx) in biopsy-naïve Japanese men. Methods: We included patients with suspect PC due to elevated PSA level or abnormal digital rectal examination, or both. csPC was defined as International Society Urological Pathology (ISUP) grade group ≥2 (csPC-A) and ISUP grade group ≥3 (csPC-B). Results: This study included 143 patients. Overall PC detection was 66.4% for SBx and 67.8% for MRI-TBx. MRI-TBx presented a significantly higher rate of csPC detection (csPC-A 67.1% vs. 58.7%, p = 0.04, and csPC-B 49.6% vs. 39.9%, p < 0.001) and significantly lower detection of non-csPC-A (0.6% vs. 6.7%). Importantly, MRI-TBx missed 4.9% (7/143) of csPC-A and only 0.7% (1/143) of csPC-B. On the other hand, SBx alone missed 13.3% (19/143) of csPC-A and 4.2% (6/143) of csPC-B. Conclusion: MRI-TBx significantly outperformed 12-cores SBx for csPC detection and decreased non-csPC detection in biopsy-naive men. Performing MRI-TBx without SBx would have missed some csPC, supporting that MRI-TBx synergizes with SBx to increase csPC detection.

    DOI: 10.1111/iju.15188

    Web of Science

    Scopus

    PubMed

  • 生検歴のない男性において融合標的生検は前立腺癌の検出能を著しく改善する(Fusion-targeted biopsy significantly improves prostate cancer detection in biopsy-naive men)

    Blas Leandro, Shiota Masaki, Tsukahara Shigehiro, Goto Shunsuke, Kinoshita Fumio, Matsumoto Takashi, Monji Keisuke, Kashiwagi Eiji, Inokuchi Junichi, Eto Masatoshi

    International Journal of Urology   30 ( 7 )   600 - 604   2023.7   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    前立腺癌(PC)が疑われる生検歴のない日本人男性において、MRI-超音波融合標的前立腺生検(TBx)と系統生検(SBx)を用いて、臨床的に重大なPC(csPC)の検出率を比較した。2020~2022年に日本の単一施設でPC疑いのためにMRI-TBx+SBxを行った143例(中央値70歳)を対象とするコホート研究を行った。csPCの定義は、国際泌尿器病理学会(ISUP)グレード群2以上(csPC-A)およびISUPグレード群3以上(csPC-B)とした。全PC検出率は、SBxで66.4%、MRI-TBxで67.8%であった。MRI-TBxはSBxに比べてcsPC検出率が有意に高く(csPC-Aは67.1 vs 58.7%、csPC-Bは49.6 vs 39.9%)、非csPC-A検出率が有意に低かった(0.6 vs 6.7%)。MRI-TBxの見逃し率はcsPC-Aは4.9%(7/143例)、csPC-Bは0.7%(1/143例)であったが、SBxではそれぞれ13.3%(19/143例)、4.2%(6/143例)であった。

  • Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy. Reviewed International journal

    @Lee K, @Shiota M, @Takamatsu D, @Ushijima M, #Blas L, #Okabe A, @Kajioka S, @Goto S, @Kinoshita F, @Matsumoto T, @Monji K, @Kashiwagi E, @Inokuchi J, @Oda Y, @Eto M:

    Int J Urol   2023.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy

    Lee, K; Shiota, M; Takamatsu, D; Ushijima, M; Blas, L; Okabe, A; Kajioka, S; Goto, S; Kinoshita, F; Matsumoto, T; Monji, K; Kashiwagi, E; Inokuchi, J; Oda, Y; Eto, M

    INTERNATIONAL JOURNAL OF UROLOGY   30 ( 4 )   340 - 346   2023.4   ISSN:0919-8172 eISSN:1442-2042

     More details

    Language:English   Publisher:International Journal of Urology  

    Objectives: To investigate the impact of extended pelvic lymph node dissection (ePLND) on urinary incontinence (UI) at early post-surgery robot-assisted radical prostatectomy (RARP). Methods: Patients who underwent RARP without cavernous nerve sparing were included between 2014 and 2019. Patient data were obtained prospectively. The associations between ePLND and postoperative urinary continence were defined as a maximum of one daily pad use. International prostate symptom score (IPSS) was examined. Expression of synaptophysin and tyrosine hydroxylase (TH) in perilymph node adipose tissue (PLA) was evaluated by immunohistochemistry. Results: In total, 186 and 163 patients underwent RARP with and without ePLND. Urinary continence rate at 1 month postoperatively among patients with ePLND was lower than those without ePLND (24.1% vs. 35.1%, p < 0.05), however, not significantly different at 3, 6, and 12 months after RARP (57.4 vs. 62.6%, 73.1 vs. 74.2%, and 83.0 vs. 81.2%, respectively). Total and voiding plus postvoiding IPSS scores at 1 month were higher in patients with ePLND than in those without ePLND (14.5 ± 0.5 vs. 13.6 ± 0.6, 7.0 ± 0.3 vs. 6.2 ± 0.4, respectively, p < 0.05). In univariate and multivariate analyses, larger prostate volume and ePLND were factors associated with an increased UI rate. Among patients who underwent ePLND, synaptophysin and TH-positive nerve fibers were detected in PLA. Conclusions: Detection of synaptophysin and TH-immunopositive nerves suggested denervation of sympathetic and peripheral nerves caused by ePLND might be associated with a higher UI rate and poor urinary symptoms at an early stage after RARP.

    DOI: 10.1111/iju.15119

    Web of Science

    Scopus

    PubMed

  • ロボット支援根治的前立腺摘出術後早期における拡大骨盤リンパ節郭清と尿失禁との相関(Correlation between extended pelvic lymph node dissection and urinary incontinence at early phase after robot-assisted radical prostatectomy)

    Lee Ken, Shiota Masaki, Takamatsu Dai, Ushijima Miho, Blas Leandro, Okabe Ayami, Kajioka Shunichi, Goto Shunsuke, Kinoshita Fumio, Matsumoto Takashi, Monji Keisuke, Kashiwagi Eiji, Inokuchi Junichi, Oda Yoshinao, Eto Masatoshi

    International Journal of Urology   30 ( 4 )   340 - 346   2023.4   ISSN:0919-8172

     More details

    Language:English   Publisher:John Wiley & Sons Australia, Ltd  

    ロボット支援根治的前立腺摘出術(RARP)後早期において拡大骨盤リンパ節郭清(ePLND)が尿失禁(UI)に及ぼす影響について検討した。海綿体神経温存を行わずにRARPを行った349例をePLND施行群186例(中央値66.5歳)とePLND非施行群163例(中央値68歳)に分類した。術後早期における排尿調節率のほか、国際前立腺症状スコア(IPSS)、リンパ節周囲脂肪組織(PLA)中のシナプトフィジンとチロシンヒドロラーゼ(TH)発現を評価した。ePLND施行群、非施行群とも術前にUIの発症はなく、術後1ヵ月における排尿調節率はePLND群が24.1%、非ePLND群が35.1%であり、ePLND群の方が有意に低かった。3、6、12ヵ月後の排尿調節率に有意な群間差はみられなかった。IPSS総スコアは1ヵ月後においてePLND群の方が有意に高く、3、6、12ヵ月後に有意差はなく、IPSS蓄尿スコアはいずれの時点でも有意な群間差はなく、IPSS排尿・排尿後症状スコアは1ヵ月後においてePLND群の方が有意に高値を示していた。多変量ロジスティック回帰分析では、前立腺容積とePLNDの施行がUI発症の独立予測因子として抽出された。ePLND群ではPLAにおいてシナプトフィジンとTH陽性神経線維が検出され、ePLNDの施行による脱神経がUI発症と関連することが示唆された。

  • 前立腺癌に対する放射線外照射療法におけるハイドロゲル留置の初期経験

    松元 崇, 後藤 駿介, 木下 史生, 李 賢, 門司 恵介, 柏木 英志, 塩田 真己, 猪口 淳一, 江藤 正俊

    日本腎泌尿器疾患予防医学研究会誌   31 ( 1 )   34 - 36   2023.3   ISSN:1347-5010

     More details

    Language:Japanese   Publisher:日本腎泌尿器疾患予防医学研究会  

    過去9ヵ月間に前立腺癌に対してSpaceOARを用いてハイドロゲルスペーサーを留置した19例(56~85歳、中央値73歳)を対象に、ハイドロゲルスペーサー留置後30日以内の合併症について検討した。その結果、合併症は2例で、1例はハイドロゲルが直腸内へ迷入、1例は前立腺被膜へ迷入した。いずれも導入初期に起きており、生理食塩水で前立腺直腸間のスペースが十分に拡がることを確認した。針先を動かさずハイドロゲルを注入することが重要である。

  • Prognostic impact of CD73/adenosine receptor 2 (A2aR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features

    Takamatsu, D; Kiyozawa, D; Kohashi, K; Goto, S; Kinoshita, F; Matsumoto, T; Ri, K; Monji, K; Kashiwagi, E; Shiota, M; Inokuchi, J; Oda, Y; Eto, M

    EUROPEAN UROLOGY   83   2023.2   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Immunophenotype analysis of tumor-infiltrating immune cells to elucidate the mechanism of antitumor effect of IL-7 and CCL19 producing CAR-T cells against solid cancer

    Goto, S; Tamada, K; Eto, M

    EUROPEAN UROLOGY   83   2023.2   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Prospective study of adoptive activated αβT lymphocyte immunotherapy for refractory cancers: development and validation of a response scoring system. Reviewed International journal

    @Nonami A, @Matsuo R, @Funakoshi K, @Nakayama T, @Goto S, @Iino T, @Takaishi S, @Mizuno S, @Akashi K, @Eto M:

    Cytotherapy   2023.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  • Prospective study of adoptive activated abT lymphocyte immunotherapy for refractory cancers: development and validation of a response scoring system

    Nonami, A; Matsuo, R; Funakoshi, K; Nakayama, T; Goto, S; Iino, T; Takaishi, S; Mizuno, S; Akashi, K; Eto, M

    CYTOTHERAPY   25 ( 1 )   76 - 81   2023.1   ISSN:1465-3249 eISSN:1477-2566

     More details

  • Denervation caused by extended pelvic lymph node dissection worsens early urinary continence after robot-assisted radical prostatectomy

    Lee, K; Shiota, M; Takamatsu, D; Ushijima, M; Okabe, A; Kajioka, S; Goto, S; Kinoshita, F; Matsumoto, T; Monji, K; Kashiwagi, E; Inokuchi, J; Oda, Y; Eto, M

    INTERNATIONAL JOURNAL OF UROLOGY   29   22 - 22   2022.10   ISSN:0919-8172 eISSN:1442-2042

     More details

  • IL-7 and CCL19 producing CAR-T cells enhance antitumor efficacy against solid cancer by preventing antigen-loss tumor relapse

    Goto, S; Tamada, K; Eto, M

    EUROPEAN UROLOGY   81   S1635 - S1636   2022.2   ISSN:0302-2838 eISSN:1873-7560

     More details

  • Human CAR-T cells producing IL-7 and CCL19 show enhanced anti-tumor efficacy against solid cancer in a PDX mouse model

    Goto, S; Tamada, K; Eto, M

    CANCER SCIENCE   113   1489 - 1489   2022.2   ISSN:1347-9032 eISSN:1349-7006

     More details

  • Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19

    Tokunaga, Y; Sasaki, T; Goto, S; Adachi, K; Sakoda, Y; Tamada, K

    MOLECULAR CANCER THERAPEUTICS   21 ( 1 )   138 - 148   2022.1   ISSN:1535-7163 eISSN:1538-8514

     More details

    Language:English   Publisher:Molecular Cancer Therapeutics  

    Although adoptive transfer of T cells genetically engineered to express chimeric antigen receptor (CAR) or T-cell receptor (TCR) has been actively developed and applied into clinic recently, further improvement of these modalities is highly demanded, especially in terms of its efficacy. Because we previously revealed the profound enhancement of antitumor effects of CAR T cells by concomitant expression of IL7 and CCL19, this study further explored a potential of IL7/CCL19 production technology to augment antitumor effects of TCR T cells. IL7/CCL19-producing P1A tumor antigen-specific TCR T cells (7 × 19 P1A T cells) demonstrated significantly improved antitumor effects, compared with those without IL7/ CCL19 production, and generated long-term memory responses. The antitumor effects of 7×19 P1A T cells were further upregulated by combination with anti–PD-1 antibody, in which blockade of PD-1 signal in both 7×19 P1A T cells and endogenous T cells plays an important role. Taken together, our study demonstrated that concomitant production of IL7 and CCL19 by genetically engineered tumor-reactive T cells could synergize with PD-1 blockade therapy to generate potent and long-lasting antitumor immunity.

    DOI: 10.1158/1535-7163.MCT-21-0400

    Web of Science

    Scopus

    PubMed

▼display all

Presentations

▼display all

MISC

  • 九州大学泌尿器科学教室における2021年から2023年の3年間の臨床統計

    辻田 次郎, 種子島 時祥, 塚原 茂大, 牟田口 淳, 後藤 駿介, 小林 聡, 松元 崇, 塩田 真己, 江藤 正俊

    西日本泌尿器科   87 ( 3 )   110 - 114   2025.2   ISSN:0029-0726

     More details

    Language:Japanese   Publisher:(一社)西日本泌尿器科学会  

    九州大学泌尿器科学教室における2021年から2023年の3年間の外来,入院および手術術式に関する統計をまとめた.1)外来患者総数は47,054人で新来2,706人,再来44,348人であり,外来新来患者疾患別頻度では,尿路性器悪性腫瘍1,514人(55.9%),悪性腫瘍等による尿路通過障害207人(7.6%),前立腺肥大症203人(7.5%),神経因性膀胱140人(5.2%),炎症性疾患103人(3.8%),尿路結石症87人(3.2%)の順であった.2)入院患者総数は3,265人で男性2,609人,女性656人で60~70歳代の男性患者が全入院患者の過半数を占めた(57.2%).入院患者疾患別では,尿路性器腫瘍が2,172人(66.5%)と最も多く,膀胱癌,前立腺癌,腎癌,腎盂尿管癌の順であった.次いで前立腺生検目的526人(16.1%),尿路結石症129人(4.0%),副腎腫瘍75人(2.3%)の順であった.3)総手術例数は1,732例で,開放手術32例(1.8%),腹腔鏡手術745例(43.0%)(うちロボット支援下手術503(29.0%)),内視鏡手術例896例(51.7%),その他74例(4.3%)であった.(著者抄録)

  • 【臨床腎・泌尿器癌(上)-基礎・臨床研究の進歩-】腎癌の治療 腎癌治療の歴史と現況

    後藤 駿介, 江藤 正俊

    日本臨床   82 ( 増刊8 臨床腎・泌尿器癌(上) )   189 - 193   2024.10   ISSN:0047-1852

     More details

    Language:Japanese   Publisher:(株)日本臨床社  

  • Current status and future perspective of immunotherapy for renal cell carcinoma(タイトル和訳中)

    Blas Leandro, Monji Keisuke, Mutaguchi Jun, Kobayashi Satoshi, Goto Shunsuke, Matsumoto Takashi, Shiota Masaki, Inokuchi Junichi, Eto Masatoshi

    International Journal of Clinical Oncology   29 ( 8 )   1105 - 1114   2024.8   ISSN:1341-9625

     More details

    Language:English   Publisher:シュプリンガー・ジャパン(株)  

  • 【泌尿器科の未来を拓く基礎研究】固形がんに対するCAR-T細胞療法の可能性

    後藤 駿介

    泌尿器科   15 ( 4 )   345 - 350   2022.4   ISSN:2435-192X

     More details

    Language:Japanese   Publisher:(有)科学評論社  

Educational Activities

  • 医学部学生講義、学生実習指導

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Surgical Clinical Medicine / Urology

Clinician qualification

  • Specialist

    日本癌治療学会、日本泌尿器内視鏡・ロボティクス学会、日本泌尿器腫瘍学会

  • Specialist

    The Japanese Urological Association

Year of medical license acquisition

  • 2011